Skip to main content

Stephen J. Nicholls, MD

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader

Professor of Cardiology

University of Adelaide

Consultant Cardiologist

Royal Adelaide Hospital

Adelaide, Australia

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Stephen Nicholls, MD

Given the results of ODYSSEY, FOURIER, and others, as a lipid/atherosclerosis specialist what is your take home about what the appetite should be for using PCSK9 inhibitors to lower LDL-C levels beyond ESC and AHA recommended thresholds of 70 mg/dL?

Given the results of ODYSSEY, FOURIER, and others, as a lipid/atherosclerosis specialist what is your take home about what the appetite should be for using PCSK9 inhibitors to lower LDL-C levels beyond ESC and AHA recommended thresholds of 70 mg/dL?

Stephen Nicholls, MD

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

Stephen Nicholls, MD

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

Stephen Nicholls, MD

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Stephen Nicholls, MD

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents?

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents?

Stephen Nicholls, MD

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

Stephen Nicholls, MD